drugset / Trial / NCT01240226

A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet

NCT01240226

Phase 1 Completed 22 enrolled Genentech, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This will be a single-center, open-label, randomized, 2-part study to determine the relative bioavailability of GDC-0941 capsule and market-image tablet formulations and the effect of ketoconazole on the pharmacokinetics of the GDC-0941 market-image tablet formulation.

Timeline

Start
2010-11
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule Oral
Subject Pictilisib Small molecule Oral

Indications

No indication recorded.